-
Ayuso happy to fly under radar at Tour de France
-
Iran leaders pay last respects to Khamenei as mourners gather
-
Curran ready to fill England gap left by Stokes exit
-
UN issues 'red alert' over 'catastrophe' in Sudan's El-Obeid
-
Djokovic has history on the line at Wimbledon
-
Tour de France to start with team time-trial 'bang'
-
Hamilton sparkles in Silverstone sunshine
-
Dressed for success: Osaka reaches Wimbledon last 16 for first time
-
Swift and Kelce set to tie the knot in glitzy arena extravaganza
-
Bayern sign Germany defender Brown until 2031
-
Police hunt for Ukrainian woman over Monaco bomb attack
-
MEXC's June Highlights: $437 Billion in Trading Volume, Offering Access to 7,000+ US Stocks and ETFs
-
Kenya's abortion taboo is killing thousands of women
-
Stocks mostly rise as beaten-down tech stocks enjoy bounce
-
Madonna returns to form with dancefloor filler "Confessions II"
-
Iranian leaders pay respects to supreme leader as Tehran prepares for funeral
-
Dean says Australia final a 'fresh start' for England
-
Doubles not a 'carnival sideshow' say players amid schedule row
-
Wimbledon giving Serena 'as much time' as possible for doubles
-
Klopp in 'talks' for Germany job after Nagelsmann exit: federation
-
Chinese investors flock to Hong Kong as trading curbs tighten
-
Surging real estate development divides opinion on Athens' riviera
-
Projected 'super typhoon' heads for US Pacific islands
-
Move over, Messi! Robot footballers thrill crowds in South Korea
-
UN warns of strong looming El Nino
-
France deaths rose by 30% during heatwave
-
Hunt for last signs of life in Venezuela quake zone
-
Drones spot sharks 73 times in two days off Sydney beaches
-
Asian markets rise as beaten-down tech stocks enjoy bounce
-
Supreme leader's body arrives at Tehran religious complex for funeral
-
David v Goliath as Cape Verde face Messi's Argentina at World Cup
-
Mbappe's French juggernaut face Paraguay, eye World Cup quarter-finals
-
Nagelsmann quits as Germany coach after World Cup exit: reports
-
Wallabies riding wave of patriotic support against Ireland
-
All Blacks return to Christchurch 'a blessing', says Savea
-
Belgium opens up Congo archives amid global minerals race
-
'Not a museum': Slovak UNESCO village strains under tourism
-
Wimbledon clings onto fashion traditions, with a twist
-
DR Congo opposition builds against presidential third-term bid
-
Death toll from massive strikes on Kyiv rises to 30
-
China sports brands score NBA stars to assist global ambitions
-
El Nino set to be strong, UN warns
-
Man dies after setting self ablaze outside UN in New York: police
-
'Inspired millions': Modric praised as World Cup career appears at end
-
VAR 'taking joy' from football says Croatia coach Dalic after loss
-
Death toll hits 10 in Thai monk procession crash
-
Afghans come home but risk exclusion without any ID
-
Asian markets rise as beaten tech stocks enjoy respite from selling
-
'Coincidence of life' says Ronaldo after Jota tribute a year from death
-
'Royal wedding': Swift and Kelce kick off star-studded celebrations
Trump signs order to fast-track research on psychedelic drugs
US President Donald Trump on Saturday announced an easing of restrictions on research into psychedelic drugs -- such as so-called "magic mushrooms" -- that have shown promise in treating people with mental health conditions.
Flanked by US Health Secretary Robert F. Kennedy Jr, top medical officials and podcaster Joe Rogan, who has pushed for access to the drugs, Trump signed an executive order that would help federal researchers cut through the red tape to allow for quicker studies.
The president said the order would "clear away unnecessary bureaucratic hurdles, improve data sharing among the FDA (Food and Drug Administration) and the Department of Veterans Affairs and facilitate fast rescheduling of any psychedelic drugs that become FDA approved."
Currently, many psychedelics including LSD and psilocybin ("magic mushrooms") are classified -- or "scheduled" -- as having high abuse and addiction potential, and are not approved for medical use, limiting the ability for scientists to study them.
If the FDA, which is charged with regulating pharmaceuticals in the United States, officially finds a medical benefit for some of the psychedelics, they could be rescheduled, allowing for greater clinical use.
The order only provides for accelerated research and does not immediately require law enforcement authorities to reclassify the drugs, meaning therapeutic use will not expand immediately.
In recent years, there has been a growing push to research the effects of the drugs in treating people -- especially war veterans -- with difficult anxiety and depression cases, especially those who had experienced traumatic stress.
Many veterans and other patients have complained that traditional antidepressant cocktails not only fail to work but change their personalities in ways that alienate them from their friends and family.
In 2023, 6,398 veterans took their own lives, the Department of Veterans Affairs said.
During the signing ceremony at the White House, Trump pointed to one drug called ibogaine, claiming patients who had taken it "experienced an 80 to 90 percent reduction in symptoms of depression and anxiety within one month."
"Can I have some, please?" he joked.
The full extent of the benefits and potential side effects of psychedelic medications is not yet known, since research has been restricted.
While many are thought to show promising mental health benefits, there are risks. Ibogaine, for instance, is thought to potentially damage the heart.
If you are a US veteran in need of help, or concerned about one, you can dial 988 and press 1, or visit www.veteranscrisisline.net.
P.M.Smith--AMWN